Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1985;78(Suppl 9):18–22.

Site-dependent response to chemotherapy for carcinoma of the breast.

J M Whitehouse
PMCID: PMC1289529  PMID: 4045914

Full text

PDF
18

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bull J. M., Tormey D. C., Li S. H., Carbone P. P., Falkson G., Blom J., Perlin E., Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649–1657. doi: 10.1002/1097-0142(197805)41:5<1649::aid-cncr2820410501>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  2. Canellos G. P., Devita V. T., Gold G. L., Chabner B. A., Schein P. S., Young R. C. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 9;1(5901):218–220. doi: 10.1136/bmj.1.5901.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Creech R. H., Catalano R. B., Harris D. T., Engstrom P. F., Grotzinger P. J. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. Cancer. 1979 Jan;43(1):51–59. doi: 10.1002/1097-0142(197901)43:1<51::aid-cncr2820430107>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  4. Creech R. H., Catalano R. B., Mastrangelo M. J., Engstrom P. F. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer. 1975 Apr;35(4):1101–1107. doi: 10.1002/1097-0142(197504)35:4<1101::aid-cncr2820350413>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  5. Decker D. A., Ahmann D. L., Bisel H. F., Edmonson J. H., Hahn R. G., O'Fallon J. R. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA. 1979 Nov 9;242(19):2075–2079. [PubMed] [Google Scholar]
  6. Gottlieb J. A., Rivkin S. E., Spigel S. C., Hoogstraten B., O'Bryan R. M., Delaney F. C., Singhakowinta A. Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study. Cancer. 1974 Feb;33(2):519–526. doi: 10.1002/1097-0142(197402)33:2<519::aid-cncr2820330229>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  7. Hancock B., Todd I. D., Wilkinson P. M. Chemotherapy of metastatic carcinoma of the breast. Clin Radiol. 1980 Jul;31(4):433–436. doi: 10.1016/s0009-9260(80)80184-x. [DOI] [PubMed] [Google Scholar]
  8. Hirshaut Y., Kesselheim H. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity. Cancer. 1983 Jun 1;51(11):1998–2004. doi: 10.1002/1097-0142(19830601)51:11<1998::aid-cncr2820511107>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Jones S. E., Durie B. G., Salmon S. E. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 1975 Jul;36(1):90–97. doi: 10.1002/1097-0142(197507)36:1<90::aid-cncr2820360104>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Legha S. S., Ajani J. A., Blumenschein G. R., Hortobagyi G. N., Buzdar A. U. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 1;53(9):1836–1840. doi: 10.1002/1097-0142(19840501)53:9<1836::aid-cncr2820530906>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  11. Manni A., Trujillo J. E., Pearson O. H. Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep. 1980 Jan;64(1):111–116. [PubMed] [Google Scholar]
  12. Mattsson W., Arwidi A., von Eyben F., Lindholm C. E. Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer. Cancer Treat Rep. 1977 Nov;61(8):1527–1531. [PubMed] [Google Scholar]
  13. Presant C. A., Van Amburg A., Klahr C. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma. Cancer. 1977 Sep;40(3):987–993. doi: 10.1002/1097-0142(197709)40:3<987::aid-cncr2820400304>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  14. Swenerton K. D., Legha S. S., Smith T., Hortobagyi G. N., Gehan E. A., Yap H. Y., Gutterman J. U., Blumenschein G. R. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May;39(5):1552–1562. [PubMed] [Google Scholar]
  15. Vogel C. L., Smalley R. V., Raney M., Krauss S., Carpenter J., Velez-Garcia E., Fishkin E., Raab S., Moore M. R., Stagg M. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. J Clin Oncol. 1984 Jun;2(6):643–651. doi: 10.1200/JCO.1984.2.6.643. [DOI] [PubMed] [Google Scholar]
  16. Yap H. Y., Benjamin R. S., Blumenschein G. R., Hortobagyi G. N., Tashima C. K., Buzdar A. U., Bodey G. P. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan;63(1):77–83. [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES